Clinical trial • Phase I • Haematology

Teclistamab for Relapsed/refractory multiple myeloma

Phase I trial of Teclistamab for Relapsed/refractory multiple myeloma.

Overview

Trial Therapeutic Area
Haematology
Trial Disease
Relapsed/refractory multiple myeloma
Trial Stage
Phase I
Drug Modality
Bispecific antibody

Key dates

Initial CTIS Submission Date
09-02-2024
First CTIS Authorization Date
03-06-2024

Trial design

Randomised, open-label, pre-change teclistamab vs post-change teclistamab (no dose or schedule specified in the provided data)-controlled Phase I trial across 29 sites in Spain, France, Germany and others.

Randomised
Yes
Open Label
Yes
Comparator
Pre-change teclistamab vs post-change teclistamab (no dose or schedule specified in the provided data)
Target Sample Size
52

Eligibility

Recruits 52 Vulnerable population selected; no information on consent or assent handling provided in the available documents..

Vulnerable Population
Vulnerable population selected; no information on consent or assent handling provided in the available documents.

Recruitment

Planned Sample Size
52
Recruitment Window Months
31
Consent Approach
No informed consent or assent process details provided in the available documents. Vulnerable population is selected but consent/assent handling is not described.

Geography

Total Number Of Sites
29
Total Number Of Participants
48

Spain

Earliest CTIS Part Ii Submission Date
28-02-2024
Latest Decision Or Authorization Date
06-02-2026
Processing Time Days
709
Number Of Sites
8
Number Of Participants
9

Sites

Site Name
Institut Catala D'oncologia
Department Name
Hematology
Principal Investigator Name
Anna Sureda
Principal Investigator Email
asureda@iconcologia.net
Contact Person Name
Anna Sureda
Contact Person Email
asureda@iconcologia.net
Site Name
Hospital Universitario 12 De Octubre
Department Name
Hematology
Principal Investigator Name
Joaquin Martinez
Principal Investigator Email
jmarti01@med.ucm.es
Contact Person Name
Joaquin Martinez
Contact Person Email
jmarti01@med.ucm.es
Site Name
Hospital Universitario Quironsalud Madrid
Department Name
Hematology
Principal Investigator Name
Carmen Martinez-Chamorro
Principal Investigator Email
carmenmartinezchamorro@hotmail.com
Contact Person Name
Carmen Martinez-Chamorro
Site Name
Hospital Universitario De Salamanca
Department Name
Hematology
Principal Investigator Name
Maria Victoria Mateos
Principal Investigator Email
mvmateos@usal.es
Contact Person Name
Maria Victoria Mateos
Contact Person Email
mvmateos@usal.es
Site Name
Hospital Clinic De Barcelona
Department Name
Hematology
Principal Investigator Name
Carlos Fernandez de Larrea
Principal Investigator Email
cfernan1@clinic.cat
Contact Person Name
Carlos Fernandez de Larrea
Contact Person Email
cfernan1@clinic.cat
Site Name
Clinica Universidad De Navarra
Department Name
Hematology
Principal Investigator Name
Paula Rodriguez
Principal Investigator Email
paurodriguez@unav.es
Contact Person Name
Paula Rodriguez
Contact Person Email
paurodriguez@unav.es
Site Name
Hospital Universitario Marques De Valdecilla
Department Name
Hematology
Principal Investigator Name
Enrique Ocio
Principal Investigator Email
ocioem@unican.es
Contact Person Name
Enrique Ocio
Contact Person Email
ocioem@unican.es
Site Name
Hospital Universitario Fundacion Jimenez Diaz
Department Name
Hematology
Principal Investigator Name
Daniel Morillo
Principal Investigator Email
dmorillo@startmadrid.com
Contact Person Name
Daniel Morillo
Contact Person Email
dmorillo@startmadrid.com

France

Earliest CTIS Part Ii Submission Date
06-05-2024
Latest Decision Or Authorization Date
02-02-2026
Processing Time Days
637
Number Of Sites
4
Number Of Participants
10

Sites

Site Name
Centre Hospitalier Universitaire De Nantes
Department Name
Hematology Department
Principal Investigator Name
Cyrille TOUZEAU
Principal Investigator Email
cyrille.touzeau@chu-nantes.fr
Contact Person Name
Cyrille TOUZEAU
Contact Person Email
cyrille.touzeau@chu-nantes.fr
Site Name
Hospices Civils De Lyon
Department Name
Hematology Department
Principal Investigator Name
Lionel KARLIN
Principal Investigator Email
lionel.karlin@chu-lyon.fr
Contact Person Name
Lionel KARLIN
Contact Person Email
lionel.karlin@chu-lyon.fr
Site Name
Centre Hospitalier Universitaire De Lille
Department Name
Blood diseases service
Principal Investigator Name
Salomon MANIER
Principal Investigator Email
salomon.manier@chu-lille.fr
Contact Person Name
Salomon MANIER
Contact Person Email
salomon.manier@chu-lille.fr
Site Name
Centre Hospitalier Universitaire De Bordeaux
Department Name
Hematology Department
Principal Investigator Name
Cyrille HULIN
Principal Investigator Email
cyrille.hulin@chu-bordeaux.fr
Contact Person Name
Cyrille HULIN
Contact Person Email
cyrille.hulin@chu-bordeaux.fr

Germany

Earliest CTIS Part Ii Submission Date
17-04-2024
Latest Decision Or Authorization Date
03-02-2026
Processing Time Days
657
Number Of Sites
4
Number Of Participants
10

Sites

Site Name
Poliklinik gGmbH Chemnitz
Department Name
Klinik für Innere Medizin III
Principal Investigator Name
Mathias Haenel
Principal Investigator Email
m.haenel@skc.de
Contact Person Name
Mathias Haenel
Contact Person Email
m.haenel@skc.de
Site Name
University Medical Center Hamburg-Eppendorf
Department Name
II. Medizinische Klinik und Poliklinik
Principal Investigator Name
Katja Weisel
Principal Investigator Email
k.weisel@uke.de
Contact Person Name
Katja Weisel
Contact Person Email
k.weisel@uke.de
Site Name
Universitaetsklinikum Wuerzburg AöR
Department Name
Medizinische Klinik und Poliklinik II
Principal Investigator Name
Leo Rasche
Principal Investigator Email
rasche_l@ukw.de
Contact Person Name
Leo Rasche
Contact Person Email
rasche_l@ukw.de
Site Name
Universitaetsklinikum Heidelberg AöR
Department Name
Innere Medizin V, Haematologie, Onkologie und Rheumatologie
Principal Investigator Name
Marc Raab
Principal Investigator Email
marc.raab@uni-heidelberg.de
Contact Person Name
Marc Raab
Contact Person Email
marc.raab@uni-heidelberg.de

Poland

Earliest CTIS Part Ii Submission Date
30-04-2024
Latest Decision Or Authorization Date
08-02-2026
Processing Time Days
649
Number Of Sites
7
Number Of Participants
9

Sites

Site Name
Centrum Onkologii Ziemi Lubelskiej Im. Sw. Jana Z Dukli
Department Name
Oddział Hematologii i Transplantacji Szpiku
Principal Investigator Name
Wojciech Legieć
Principal Investigator Email
legiec.wojciech@gmail.com
Contact Person Name
Wojciech Legieć
Contact Person Email
legiec.wojciech@gmail.com
Site Name
Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej
Department Name
Oddział Hematologii
Principal Investigator Name
Piotr Centkowski
Principal Investigator Email
pcentek@wp.pl
Contact Person Name
Piotr Centkowski
Contact Person Email
pcentek@wp.pl
Site Name
Dolnoslaskie Centrum Onkologii Pulmonologii I Hematologii
Department Name
Centrum Hematologiczno-Transplantacyjne
Principal Investigator Name
Jarosław Dybko
Principal Investigator Email
jaroslaw.dybko@dcopih.pl
Contact Person Name
Jarosław Dybko
Contact Person Email
jaroslaw.dybko@dcopih.pl
Site Name
Medical University Of Warsaw
Department Name
Klinika Hematologii, Transplantologii i Chorób Wewnętrznych
Principal Investigator Name
Krzysztof Jamroziak
Principal Investigator Email
krzysztof.jamroziak@wum.edu.pl
Contact Person Name
Krzysztof Jamroziak
Contact Person Email
krzysztof.jamroziak@wum.edu.pl
Site Name
Uniwersyteckie Centrum Kliniczne
Department Name
Klinika Hematologii i Transplantologii
Principal Investigator Name
Agata Tyczyńska
Principal Investigator Email
atyczynska@uck.gda.pl
Contact Person Name
Agata Tyczyńska
Contact Person Email
atyczynska@uck.gda.pl
Site Name
Swietokrzyskie Centrum Onkologii Samodzielny Publiczny Zaklad Opieki Zdrowotnej W Kielcach
Department Name
Klinika Hematologii i Transplantacji Szpiku
Principal Investigator Name
Paweł Steckiewicz
Principal Investigator Email
badania.kliniczne@onkol.kielce.pl
Contact Person Name
Paweł Steckiewicz
Site Name
Pratia Hematologia Sp. z o.o.
Department Name
Pratia Onkologia Katowice
Principal Investigator Name
Sebastian Grosicki
Principal Investigator Email
sgrosicki@wp.pl
Contact Person Name
Sebastian Grosicki
Contact Person Email
sgrosicki@wp.pl

Italy

Earliest CTIS Part Ii Submission Date
23-04-2024
Latest Decision Or Authorization Date
04-02-2026
Processing Time Days
652
Number Of Sites
6
Number Of Participants
10

Sites

Site Name
Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII
Department Name
UO Ematologia
Principal Investigator Name
Monica Galli
Principal Investigator Email
monicagalli@asst-pg23.it
Contact Person Name
Monica Galli
Contact Person Email
monicagalli@asst-pg23.it
Site Name
Azienda Ospedaliero Universitaria Delle Marche
Department Name
SOD Clinica Ematologica
Principal Investigator Name
Massimo Offidani
Principal Investigator Email
massimo.offidani@ospedaliriuniti.marche.it
Contact Person Name
Massimo Offidani
Site Name
Azienda Ospedaliero Universitaria Pisana
Department Name
UO Ematologia
Principal Investigator Name
Gabriele Buda
Principal Investigator Email
g.buda@ao-pisa.toscana.it
Contact Person Name
Gabriele Buda
Contact Person Email
g.buda@ao-pisa.toscana.it
Site Name
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Department Name
UO Ematologia
Principal Investigator Name
Valerio De Stefano
Principal Investigator Email
valerio.destefano@unicatt.it
Contact Person Name
Valerio De Stefano
Contact Person Email
valerio.destefano@unicatt.it
Site Name
Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia
Department Name
UO Ematologia
Principal Investigator Name
Angelo Belotti
Principal Investigator Email
angelo.belotti@asst-spedalicivili.it
Contact Person Name
Angelo Belotti
Site Name
Istituto Romagnolo Per Lo Studio Dei Tumori Dino Amadori IRST S.r.l.
Department Name
UO Oncoematologia
Principal Investigator Name
Claudio Cerchione
Principal Investigator Email
claudio.cerchione@irst.emr.it
Contact Person Name
Claudio Cerchione
Contact Person Email
claudio.cerchione@irst.emr.it

Sponsor

Primary sponsor

Full Name
Janssen Cilag International
Organisation Type
Pharmaceutical company
Country Of Registered Address
Belgium

Investigational products

Investigational Product Name
Teclistamab
Active Substance
Teclistamab
Modality
Bispecific antibody

Related trials

Other published trials that may interest you.